Clinicopathological and immunohistochemical characteristics in male breast cancer: A retrospective case series

Oncologist

Volumn 20, Issue 6, 2015, Pages 586-592

  Masci, Giovanna ^a   Caruso, Michele ^b   Caruso, Francesco ^b   Salvini, Piermario ^c   Carnaghi, Carlo ^d   Giordano, Laura ^a   Miserocchi, Vittoria ^a   Losurdo, Agnese ^a   Zuradelli, Monica ^a   Torrisi, Rosalba ^a   Tommaso, Luca Di ^a   Tinterri, Corrado ^a   Testori, Alberto ^a   Garcia Etienne, Carlos A ^a   Gatzemeier, Wolfgang ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Humanitas Centro Catanese di Oncologia   (Italy)

^c Humanitas Gavazzeni Hospital   (Italy)

^d Cardiology Department Mater Domini   (Italy)

Author keywords

Breast neoplasm; Clinic opathological features; HER 2 expression; Ki 67 index; Male breast cancer

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; KI 67 ANTIGEN; LAPATINIB; LETROZOLE; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER STAGING; COLORECTAL CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALE BREAST CANCER; METASTASIS; PAGET NIPPLE DISEASE; PARTIAL MASTECTOMY; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT DISEASE; RETROSPECTIVE STUDY; SARCOMA; SECOND CANCER; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84932624685     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0243     Document Type: Article

References (25)

1. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006;367:595-604.
2. White J, Kearins O, Dodwell D et al. Male breast carcinoma: Increased awareness needed. Breast Cancer Res 2011;13:219.
3. Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat 2009; 115:429-430.
4. Ottini L, Palli D, RizzoSetal. Male breast cancer. Crit Rev Oncol Hematol 2010;73:141-155.
5. Dimitrov NV, Colucci P, Nagpal S. Some aspects of the endocrine profile and management of hormone-dependent male breast cancer. The Oncologist 2007;12:798-807.
6. Murphy CE, Carder PJ, Lansdown MR et al. Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol 2006;32:44-47.
7. Rudlowski C, Friedrichs N, Faridi A et al. Her-2/ neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004;84:215-223.
8. Curigliano G, Colleoni M, Renne G et al. Recognizing features that are dissimilar in male and female breast cancer: Expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol 2002;13:895-902.
9. Tawil AN, Boulos FI, Chakhachiro ZI et al. Clinico-pathologic and immunohistochemical characteristics of male breast cancer: A single center experience. Breast J 2012;18:65-68.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The Value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19: 403-410.
11. Yerushalmi R, Woods R, Ravdin PM et al. Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol 2010;11:174-183.
12. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24: 2206-2223.
13. Ruddy KJ, Winer EP. Male breast cancer: Risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 2013;24:1434-1443.
14. Korde LA, Zujewski JA, Kamin L et al. Multidis-ciplinary meeting on male breast cancer: Summary and research recommendations. J Clin Oncol 2010; 28:2114-2122.
15. Masci G, Gandini C, Zuradelli M et al. Fulves-trant for advanced male breast cancer patients: A case series. Ann Oncol 2011;22:985.
16. Di Lauro L, Vici P, Del Medico P et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat 2013;141:119-123.
17. Zagouri F, Sergentanis TN, Koutoulidis V et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: A case series. Br J Cancer 2013;108: 2259-2263.
18. Bradley KL, Tyldesley S, Speers CH et al. Contemporary systemic therapy for male breast cancer. Clin Breast Cancer 2014;14:31-39.
19. Hayashi H, Kimura M, Yoshimoto N et al. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzu-mab and paclitaxel treatment. Breast Cancer 2009; 16:136-140.
20. Schaapveld M, Visser O, Louwman MJ et al. Risk of new primary non breast cancers after breast cancer treatment: A Dutch population-based study. J Clin Oncol 2008;26:1239-1246.
21. Mellemkjær L, Christensen J, Frederiksen K et al. Riskof primary non-breast cancer after female breast cancer by age at diagnosis. Cancer Epidemiol Biomarkers Prev 2011;20:1784-1792.
22. Satram-Hoang S, Ziogas A, Anton-Culver H. Risk of second primary cancer in men with breast cancer. Breast Cancer Res 2007;9:R10.
23. Lee UJ, Jones JS. Incidence of prostate cancer in male breast cancer patients: A risk factor for prostate cancer screening. Prostate Cancer Prostatic Dis 2009;12:52-56.
24. 24. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99:929-935.
25. 25. Hemminki K, Scelo G, Boffetta P et al. Second primary malignancies in patients with male breast cancer. Br J Cancer 2005;92:1288-1292.